"While KYNAMRO is our flagship drug, our pipeline goes well beyond KYNAMRO. With drugs in numerous therapeutic areas, we have many opportunities for both short- and long-term revenue growth. We have several drugs that may provide substantial commercial opportunities with product launches that could occur within the next five years. These include our TTR amyloidosis and Spinal Muscular Atrophy drugs from our severe and rare disease franchise, which, due to the significant unmet medical need and orphan patient populations, could warrant an accelerated path to market. We expect that, if successful, they could be available for patients within the next five years. In addition, we are implementing a staged development path for our triglyceride-lowering drug, ISIS-APOCIIIRx, that could bring this important new medicine to the market sooner for patients with extremely high and poorly controlled triglycerides who, as a result, are at severe risk of disease," continued Ms. Parshall.
"In addition to the potential near-term product opportunities in our pipeline, we have several drugs that could represent significant licensing opportunities in the next year or two. With robust Phase 2 data packages, we may be able to command lucrative licensing terms for these drugs. Among these near-term licensing opportunities is our anticoagulant drug targeting Factor XI and our CRP drug from our cardiovascular franchise. Both of these drugs have the potential to treat numerous diseases with significant market potential. In addition, we have several drugs from our metabolic franchise that could complete Phase 2 studies in the next two years and could also provide significant licensing opportunities. These drugs represent novel approaches to the treatment of type 2 diabetes
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved